Instrumento Inactivo

Acciones Durata Therapeutics Inc

Acciones

Precio de cierre Nasdaq Otros sitios de cotización
- ^USD	-

Durata Therapeutics : Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults	01/06/15
Durata Therapeutics : Infectious Disease Experts, Scientists and Clinicians Join Forces on SHARE ID™ to Accelerate the Battle Against Antibiotic-resistant Infections	27/05/15
Durata Therapeutics : Actavis Confirms Generic Letairis® Patent Challenge	08/04/15
Durata Therapeutics : Actavis Announces Michael R. Gallagher and Peter J. McDonnell to Join Board of Directors	03/04/15
Durata Therapeutics : Actavis and Allergan Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Allergan	12/03/15

Sector

	Varia. 1 de ene.	Capi.
MODERNA, INC.	+25,69 %	47,86 mil M
LONZA GROUP AG	+46,90 %	41,42 mil M
IQVIA HOLDINGS INC.	-3,46 %	40,66 mil M
CELLTRION, INC.	-6,20 %	28,92 mil M
ICON PUBLIC LIMITED COMPANY	+9,17 %	25,55 mil M
ALNYLAM PHARMACEUTICALS, INC.	-20,42 %	19,27 mil M
MEDPACE HOLDINGS, INC.	+28,07 %	12,14 mil M
BIO-TECHNE CORPORATION	+0,17 %	12,15 mil M
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1,24 %	11,99 mil M